FAP‐1‐mediated activation of NF‐κB induces resistance of head and neck cancer to fas‐induced apoptosis
Open Access
- 3 August 2006
- journal article
- research article
- Published by Wiley in Journal of Cellular Biochemistry
- Vol. 100 (1), 16-28
- https://doi.org/10.1002/jcb.20922
Abstract
Molecular mechanisms responsible for tumor resistance to apoptosis often involve the Fas/FasL pathway. While squamous cell carcinomas of the head and neck (SCCHN) express both Fas and FasL, their resistance to self-induced apoptosis or apoptosis mediated by Fas agonistic antibody (CH-11Ab) was independent of the level of Fas surface expression or the presence of soluble Fas in supernatants of primary or metastatic SCCHN cell lines. By in vitro immunoselection, using PCI-15A cell line treated with successive cycles of CH-11 Ab, Fas-resistant sublines with the parental genotype were selected. Such sublines failed to cleave caspase-8 upon Fas engagement and were resistant to CH-11 Ab, although they remained sensitive to VP-16 or staurosporin. In the presence of cycloheximide, the selected SCCHN sublines become susceptible to CH-11 Ab, and showed cleavage of caspase-8, suggesting that apoptosis resistance was mediated by an inhibitory protein(s) acting upstream of caspase-8. Overexpression of Fas-associated phosphatase 1 (FAP-1), but not cellular FLICE-inhibitory protein (cFLIP) in SCCHN sublines was documented by Western blots and RT-PCR analyses. The FAP-1+ selected sublines also downregulated cell surface Fas. A high phosphorylation level of IκBκ, NFκB activation and upregulation of Bcl-2 expression were observed in the FAP-1+ sublines. Treatment with the phosphatase inhibitor, orthovanadate, or silencing of FAP-1 with siRNA abolished their resistance to apoptosis, suggesting that FAP-1 phosphatase activity could be responsible for NF-κB activation and resistance of SCCHN cells to Fas-mediated apoptosis. J. Cell. Biochem. 100: 16–28, 2007.Keywords
This publication has 38 references indexed in Scilit:
- NF-κB-independent actions of sulfasalazine dissociate the CD95L- and Apo2L/TRAIL-dependent death signaling pathways in human malignant glioma cellsCell Death & Differentiation, 2003
- Soluble Fas (sFas) and soluble Fas ligand (sFas-L) balance in laryngeal carcinoma before and after surgical treatmentJournal of Surgical Oncology, 2003
- FAP-1 Association with Fas (Apo-1) Inhibits Fas Expression on the Cell SurfaceMolecular and Cellular Biology, 2003
- Usage of the NF‐κB inhibitor sulfasalazine as sensitizing agent in combined chemotherapy of pancreatic cancerInternational Journal of Cancer, 2003
- Expression and Potential Role of Fas-Associated Phosphatase-1 in Ovarian CancerThe American Journal of Pathology, 2001
- How NF-κB is activated: the role of the IκB kinase (IKK) complexOncogene, 1999
- Immunohistochemical localization of FAP‐1, an inhibitor of Fas‐mediated apoptosis, in normal and neoplastic human tissuesAPMIS, 1999
- NF-κB AND REL PROTEINS: Evolutionarily Conserved Mediators of Immune ResponsesAnnual Review of Immunology, 1998
- Protection from Fas-Mediated Apoptosis by a Soluble Form of the Fas MoleculeScience, 1994
- Molecular cloning of a novel protein‐tyrosine phosphatase containing a membrane‐binding domain and GLGF repeatsFEBS Letters, 1994